Use of high-throughput LC–MS/MS proteomics technologies in drug discovery

Significant improvements have been made during the past few years in technologies for high-throughput proteomics based on mass spectrometry. As proteomics technologies advance and become more widely accessible, efforts to profile and quantify full proteomes are underway to complement other genomics approaches, such as transcript and metabolite profiling. Of particular interest is the application of proteomics to protein biomarker discovery, which is increasingly being recognized as crucially important for the study of disease processes, both from the diagnostic and prognostic points of view. This review will discuss the advances and current limitations of full proteome analysis for biomarker discovery, including deep proteome profiling, quantitative proteomics, and phosphoproteome profiling.

Section editors:Li-he Zhang – School of Pharmaceutical Science, Peking University, Beijing, ChinaKaixian Chen – Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China